Search results for "medicine.hormone"

showing 10 items of 48 documents

Estrogens inhibit angiotensin II-induced leukocyte-endothelial cell interactions in vivo via rapid endothelial nitric oxide synthase and cyclooxygena…

2002

Angiotensin II (Ang II) may be a key molecule in the development of atherosclerosis. Because the incidence of coronary atherosclerosis in premenopausal women is lower than that observed in men or postmenopausal women, we have investigated the effect of estrogens on Ang II–induced leukocyte recruitment in vivo using intravital microscopy in the rat mesenteric microcirculation. Superfusion for 60 minutes with Ang II induced a significant increase in leukocyte rolling flux, adhesion, and emigration. Administration of 17-β-estradiol (17-β-E) after 30 minutes of Ang II superfusion produced a reduction of these leukocyte responses by 55.1%, 72.7%, and 70.9%, respectively, an additional 30 minutes…

MaleSelective Estrogen Receptor Modulatorsmedicine.medical_specialtyEndotheliumPhysiologyLeukocyte RollingProstacyclinCell CommunicationBiologyIn Vitro TechniquesLosartanReceptor Angiotensin Type 1Lymphatic SystemRats Sprague-DawleyAngiotensin Receptor AntagonistsCell MovementInternal medicinemedicineCell AdhesionLeukocytesAnimalsHumansSplanchnic CirculationEnzyme InhibitorsCells CulturedVenuleEstradiolAngiotensin IIEstrogen AntagonistsAntibodies MonoclonalEstrogensAngiotensin IIEpoprostenolRatsEndothelial stem cellNitric oxide synthasemedicine.anatomical_structureEndocrinologyProstaglandin-Endoperoxide Synthasesbiology.proteinEndothelium VascularNitric Oxide SynthaseCardiology and Cardiovascular Medicinehormones hormone substitutes and hormone antagonistsIntravital microscopymedicine.drugCirculation research
researchProduct

Estradiol reduces F2α-isoprostane production in cultured human endothelial cells

2002

Free radical-generated F2α-isoprostanes are a group of compounds with vasoconstrictor properties. To investigate whether estradiol exerts antioxidant actions modifying F2α-isoprostane production, cultured human umbilical vein endothelial cells were exposed to estradiol and other compounds and F2α-isoprostanes were measured in culture medium. Exposure to 1 and 10 nM estradiol for 24 h reduced F2α-isoprostane production by 36 and 49%, respectively ( P < 0.001 vs. control). Exposure to antiestrogens alone (ICI-182780 or EM-652) slightly reduced F2α-isoprostanes ( P < 0.05 vs. control), but much less than exposure to estradiol ( P < 0.05). ICI-182780 reversed the estradiol-induced redu…

MaleUmbilical Veinsmedicine.medical_specialtyAntioxidantIsoprostaneEndotheliumPhysiologymedicine.drug_classmedicine.medical_treatmentMedroxyprogesterone AcetateIsoprostanesBiologymedicine.disease_causeUmbilical veinchemistry.chemical_compoundPiperidinesPhysiology (medical)Internal medicinemedicineHumansFulvestrantCells CulturedProgesteroneDose-Response Relationship DrugEstradiolProgesterone CongenersEstrogen AntagonistsInfant NewbornEndothelial stem cellEndocrinologymedicine.anatomical_structurechemistryCell cultureEstrogenCulture Media ConditionedFemaleEndothelium VascularCardiology and Cardiovascular Medicinehormones hormone substitutes and hormone antagonistsOxidative stressAmerican Journal of Physiology-Heart and Circulatory Physiology
researchProduct

Multiple marker approach to risk stratification in patients with stable coronary artery disease

2010

Aims Multimarker approaches for risk prediction in coronary artery disease have remained inconsistent. We assessed multiple biomarkers representing distinct pathophysiological pathways in relation to cardiovascular events in stable angina. Methods and results We investigated 12 biomarkers reflecting inflammation [C-reactive protein, growth-differentiation factor (GDF)-15, neopterin], lipid metabolism (apolipoproteins AI, B100), renal function (cystatin C, serum creatinine), and cardiovascular function and remodelling [copeptin, C-terminal-pro-endothelin-1, mid-regional-pro-adrenomedullin (MR-proADM), mid-regional-pro-atrial natriuretic peptide (MR-proANP), N-terminal-pro-B-type natriuretic …

Malemedicine.hormonemedicine.medical_specialtymedicine.drug_classMyocardial InfarctionCoronary Artery DiseaseKaplan-Meier EstimateRisk AssessmentAnginaCoronary artery diseaseEndothelinsCopeptinInternal medicinemedicineNatriuretic peptideHumansAngina StableProspective StudiesRisk factorAgedbiologybusiness.industryHazard ratioMiddle AgedPrognosismedicine.diseaseEndocrinologyCystatin Cbiology.proteinCardiologyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersEuropean Heart Journal
researchProduct

Contributions of ACE and mast cell chymase to endogenous angiotensin II generation and leucocyte recruitment in vivo

2011

Aims In vitro studies suggest that mast cell chymase (MCP) is more important than angiotensin-converting enzyme (ACE) for generating angiotensin II (Ang II) within the cardiovascular system. We investigated in vivo the relative contributions of ACE and MCP to leucocyte recruitment induced by endogenously generated Ang II. Methods and results Exposure of the murine cremasteric microcirculation of C57BL/6 mice to Ang I (100 nM for 4 h) induced leucocyte–endothelium interactions. Either losartan (an Ang II receptor-1 antagonist, AT1) or enalapril (an ACE inhibitor), but not chymostatin (a chymase inhibitor), inhibited Ang I-induced responses. Mast cell degranulation with compound 48/80 (CMP48/…

Malemedicine.medical_specialtyPhysiologymedicine.drug_classReceptor expressionPeptidyl-Dipeptidase AReceptor Angiotensin Type 1MiceChymasesCell MovementPhysiology (medical)Internal medicineLeukocytesmedicineAnimalsp-Methoxy-N-methylphenethylamineMast CellsMast cell stabilizerEnalaprilAngiotensin II receptor type 1ChemistryAngiotensin IIChymaseAngiotensin IIMice Inbred C57BLEndocrinologyLosartanACE inhibitorcardiovascular systemAngiotensin ICardiology and Cardiovascular Medicinehormones hormone substitutes and hormone antagonistsmedicine.drugCardiovascular Research
researchProduct

Acute hormonal and neuromuscular responses and recovery to forced vs maximum repetitions multiple resistance exercises.

2003

Acute hormonal and neuromuscular responses and recovery three days after the exercises were examined during the maximum repetitions (MR) and forced repetitions (FR) resistance exercise protocols in 16 male athletes. MR included 4 sets of leg presses, 2 sets of squats and 2 sets of knee extensions (with 12 RM) with a 2-min recovery between the sets and 4 min between the exercises. In FR the initial load was chosen to be higher than in MR so that the subject could not lift 12 repetitions per set by himself. After each set to failure the subject was assisted to perform the remaining repetitions to complete the 12 repetitions per set. Thus the exercise intensity was greater in FR than in MR. Bo…

Malemedicine.medical_specialtyTime FactorsHydrocortisoneWeight LiftingPainPhysical Therapy Sports Therapy and RehabilitationIsometric exerciseElectromyographyPhysical medicine and rehabilitationInternal medicineIsometric ContractionMedicineHumansOrthopedics and Sports MedicineHormone metabolismTestosteroneLactic AcidExercise physiologyMuscle SkeletalExerciseSerum testosteronemedicine.diagnostic_testbusiness.industryElectromyographyHuman Growth HormoneResistance trainingHormonesElectrophysiologyExercise intensityCardiologybusinessHormoneInternational journal of sports medicine
researchProduct

Impact of Chemical Endocrine Disruptors and Hormone Modulators on the Endocrine System

2022

There is growing concern regarding the health and safety issues of endocrine-disrupting chemicals (EDCs). Long-term exposure to EDCs has alarming adverse health effects through both hormone-direct and hormone-indirect pathways. Non-chemical agents, including physical agents such as artificial light, radiation, temperature, and stress exposure, are currently poorly investigated, even though they can seriously affect the endocrine system, by modulation of hormonal action. Several mechanisms have been suggested to explain the interference of EDCs with hormonal activity. However, difficulty in quantifying the exposure, low standardization of studies, and the presence of confounding factors do n…

Malephthalatephysical agentsbeta-cellEndocrine SystemtestisEndocrine Disruptorsthyroid.CatalysisthyroidInorganic ChemistrybisphenolHumansparathyroidPhysical and Theoretical ChemistryMolecular BiologySpectroscopyphthalatesV.Organic ChemistryGeneral MedicineHormonestestiComputer Science Applicationsphysical agentadrenalFemaleovary
researchProduct

2021

ObjectiveLoss of sex hormones has been suggested to underlie menopause-associated increment in cardiovascular risk. We investigated associations of sex hormones with arterial stiffness in 19–58-years-old women. We also studied associations of specific hormonal stages, including natural menstrual cycle, cycle with combined oral contraceptives (COC) and menopausal status with or without hormone therapy (HT), with arterial stiffness.MethodsThis study includes repeated measurements of 65 healthy women representing reproductive (n=16 natural, n=10 COC-users) and menopause (n=5 perimenopausal, n=26 postmenopausal, n=8 HT-users) stages. Arterial stiffness outcomes were aortic pulse wave velocity (…

Mean arterial pressurebusiness.industryEndocrinology Diabetes and Metabolismmedia_common.quotation_subjectmedicine.medical_treatmentPhysiologymedicine.diseaseMenopauseHormonal contraceptionTransgender hormone therapyArterial stiffnessMedicineHormone therapybusinessPulse wave velocityMenstrual cyclemedia_commonFrontiers in Endocrinology
researchProduct

New molecular targets in bone metastases.

2010

Bone metastases have a major impact on morbidity and on mortality in cancer patients. Despite its clinical relevance, metastasis remains the most poorly elucidated aspect of carcinogenesis. The biological mechanisms leading to bone metastasis establishment have been referred as " vicious circle," a complex network between cancer cells and the bone microenvironment. This review is aimed to underline the new molecular targets in bone metastases management other than bisphosphonates. Different pathways or molecules such as RANK/RANKL/OPG, cathepsin K, endothelin-1, Wnt/DKK1, Src have recently emerged as potential targets and nowadays preclinical and clinical trials are underway. The results fr…

Oncologymedicine.hormonemedicine.medical_specialtyPathologyCathepsin KProto-Oncogene Proteins pp60(c-src)Antineoplastic AgentsBone NeoplasmsBone NeoplasmAntibodies Monoclonal HumanizedEndothelinMetastasisAntineoplastic AgentEndothelinsBone metastases; Molecular targets; Animals; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antineoplastic Agents; Bone Neoplasms; Cathepsin K; Denosumab; Endothelins; Humans; Proto-Oncogene Proteins pp60(c-src); RANK Ligand; Medicine (all); Oncology; Radiology Nuclear Medicine and ImagingInternal medicineMedicineAnimalsHumansRadiology Nuclear Medicine and imagingMolecular targetbiologyAnimalbusiness.industryMedicine (all)EndothelinsRANK LigandCancerBone metastasisAntibodies MonoclonalGeneral Medicinemedicine.diseaseClinical trialBone metastaseDenosumabOncologyRANKLCancer cellbiology.proteinDenosumabbusinessHumanmedicine.drugCancer treatment reviews
researchProduct

Breast cancer in men in Cote d'Or (France): epidemiological characteristics, treatments and prognostic factors

2012

Breast cancer in men is rare, and clinical trials are thus not feasible. This study aimed to describe the epidemiological characteristics, treatment and prognostic factors of breast cancer in men. A population-based study was performed using data from the Cote d'Or breast and gynaecological cancer registry. Data on male breast cancer diagnosed from 1982 to 2008 were provided. Relative survival rates were estimated at 5 years according to the characteristics of the patient and tumour, and treatment. Prognostic factors of survival in men with breast cancer were identified using a generalised linear model. Seventy-five men with invasive breast cancer were registered. Mean age at diagnosis was …

Oncologymedicine.medical_specialtyeducation.field_of_studyRelative survivalbusiness.industrymedicine.medical_treatmentPopulationmedicine.diseaseRadiation therapyBreast cancerOncologyInternal medicineMale breast cancerEpidemiology of cancermedicineHormone therapybusinesseducationSurvival analysisEuropean Journal of Cancer Care
researchProduct

Potentiation by vasopressin of adrenergic vasoconstriction in the rat isolated mesenteric artery

1997

1. The aim of the present study was to investigate in rat mesenteric artery rings whether low concentrations of vasopressin could modify the contractile responses to noradrenaline and electrical stimulation of perivascular nerves. 2. Vasopressin (10[10]-10[-7] M) caused concentration-dependent contractions (pD2 = 8.36+/-0.09). The V1-receptor antagonist d(CH2)5Tyr(Me)AVP (10[-9]-10[-8] M) produced parallel rightward shifts of the control curve for vasopressin. Schild analysis yielded a pA2 value of 9.83 with a slope of 1.10+/-0.14. 3. Vasopressin (3 x 10[-10] and 10[-9] M) caused concentration-dependent potentiation of the contractions elicited by electrical stimulation (2-8 Hz; 0.2 ms dura…

PharmacologyAgonistmedicine.medical_specialtyVasopressinmedicine.drug_classAntagonistAdrenergicStimulationVasotocinchemistry.chemical_compoundEndocrinologychemistryInternal medicinemedicinehormones hormone substitutes and hormone antagonistsVasopressin AntagonistsVasopressin receptorBritish Journal of Pharmacology
researchProduct